Anti-TNF-α therapy for orofacial granulomatosis: proceed with caution
Anti-TNF-α therapy for orofacial granulomatosis: proceed with caution
复制标题
DOI：
10.1136/gut.2006.099143
复制
发表时间：
2006-09
期刊：
影响因子：
24.5
通讯作者：
D. Gaya;S. Aitken;J. Fennell;J. Satsangi;A. Shand
中科院分区：
文献类型：
--
作者：
D. Gaya;S. Aitken;J. Fennell;J. Satsangi;A. Shand
我们饶有兴趣地阅读了Ardizzone及其同事的研究（Gut 2006; 55: 47-53）和Sands （Gut 2006; 55: 437-41）关于硫唑嘌呤（AZA）治疗溃疡性结肠炎的疗效和副作用的优秀综述。Ardizzone等人在他们的研究者盲法研究中观察到，在包括类固醇依赖性溃疡性结肠炎患者的研究中，硫唑嘌呤治疗的轻至中度不良事件多于美萨拉明（5-ASA）治疗的患者（26% vs 6%; p = 0.046）。然而，36例服用AZA的患者中只有2例因不良事件退出研究。我们在一项双盲、双虚拟、随机、前瞻性、多中心研究中观察到AZA （2.0-2.5 mg/kg/天）和5-ASA （4 g/天）预防克罗恩病术后内镜下复发的有效性和安全性。79例(AZA， 42例；
We read with great interest the study by Ardizzone and colleagues ( Gut 2006; 55 :47–53) and the excellent review of Sands ( Gut 2006; 55 :437–41) commenting on the efficacy and side effects of azathioprine (AZA) in the therapy of ulcerative colitis. Ardizzone et al observed in their investigator blinded study, which included patients with steroid dependent ulcerative colitis, more mild to moderate adverse events in azathioprine than in mesalamine (5-ASA) treated patients (26% v 6%; p = 0.046). However, only two of 36 patients on AZA were withdrawn from the study because of adverse events. We would like to comment on the side effects of AZA, which we observed in a double blind, double dummy, randomised, prospective, multicentre study on the efficacy and safety of AZA (2.0–2.5 mg/kg/day) and 5-ASA (4 g/day) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Seventy nine patients (AZA, 42; …